KalVista Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de KalVista Pharmaceuticals' es Ben Palleiko , nombrado en Mar 2024, tiene una permanencia de menos de un año. compensación anual total es $2.42M, compuesta por 21.3% salario y 78.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.44% de las acciones de la empresa, por valor de €2.03M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 5.2 años, respectivamente.

Información clave

Ben Palleiko

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	21.3%
Permanencia del CEO	less than a year
Participación del CEO	0.4%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ben Palleiko en comparación con los beneficios de KalVista Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jan 31 2024	n/a	n/a	-US$108m
Oct 31 2023	n/a	n/a	-US$101m
Jul 31 2023	n/a	n/a	-US$95m
Apr 30 2023	US$2m	US$515k	-US$93m
Jan 31 2023	n/a	n/a	-US$91m
Oct 31 2022	n/a	n/a	-US$92m
Jul 31 2022	n/a	n/a	-US$89m
Apr 30 2022	US$3m	US$490k	-US$82m
Jan 31 2022	n/a	n/a	-US$73m
Oct 31 2021	n/a	n/a	-US$61m
Jul 31 2021	n/a	n/a	-US$52m
Apr 30 2021	US$1m	US$435k	-US$46m
Jan 31 2021	n/a	n/a	-US$38m
Oct 31 2020	n/a	n/a	-US$37m
Jul 31 2020	n/a	n/a	-US$33m
Apr 30 2020	US$1m	US$435k	-US$29m
Jan 31 2020	n/a	n/a	-US$31m
Oct 31 2019	n/a	n/a	-US$26m
Jul 31 2019	n/a	n/a	-US$23m
Apr 30 2019	US$2m	US$366k	-US$21m
Jan 31 2019	n/a	n/a	-US$13m
Oct 31 2018	n/a	n/a	-US$14m
Jul 31 2018	n/a	n/a	-US$16m
Apr 30 2018	US$821k	US$340k	-US$16m

Compensación vs. Mercado: La compensación total de Ben($USD2.42M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD986.47K).

Compensación vs. Ingresos: La compensación de Ben ha sido consistente con los resultados de la empresa en el último año.

CEO

Ben Palleiko (57 yo)

less than a year

Permanencia

US$2,420,747

Compensación

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Benjamin Palleiko	CEO & Director	less than a year	US$2.42m	0.44% $ 2.1m
Christopher Yea	Chief Development Officer	8.5yrs	US$1.65m	0.17% $ 817.3k
Edward Feener	Chief Scientific Officer	7.5yrs	US$1.59m	0.15% $ 696.9k
Ryan Baker	Head of Investor Relations	no data	sin datos	sin datos
Brian Krex	General Counsel	no data	sin datos	sin datos
Jarrod Aldom	Vice President of Corporate Communications	no data	sin datos	sin datos
Rachel Morten	Senior Vice President of Regulatory Affairs & QA	no data	sin datos	sin datos
Michael Smith	Senior Vice President of Development	5yrs	sin datos	sin datos
Paul Audhya	Chief Medical Officer	3yrs	sin datos	0.13% $ 593.0k
Nicole Sweeny	Chief Commercial Officer	less than a year	sin datos	sin datos
Stephen Donnelly	Director of Finance and Company Secretary	no data	sin datos	sin datos

4.0yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4XC1 se considera experimentado (3.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Benjamin Palleiko	CEO & Director	less than a year	US$2.42m	0.44% $ 2.1m
Edward Unkart	Independent Director	9.4yrs	US$94.06k	0% $ 0
Albert Cha	Independent Director	16.5yrs	US$89.06k	0% $ 0
Brian J. Pereira	Independent Chairman	5.3yrs	US$107.85k	0% $ 0
Nancy Stuart	Independent Director	3.2yrs	US$89.58k	0% $ 0
William Fairey	Director	less than a year	sin datos	sin datos
Tomas Kiselak	Board Observer	8.8yrs	sin datos	sin datos
Patrick Treanor	Independent Director	2yrs	US$159.18k	0% $ 0

4.2yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 4XC1 se considera experimentada (5.2 años de antigüedad promedio).

KalVista Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. Announces Board Changes

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Recent updates

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

New minor risk - Profitability

New major risk - Financial position

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

No longer forecast to breakeven

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee

Revenue misses expectations

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

New 90-day low: €12.50

Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus

Revenue misses expectations

Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020

New 90-day high: €16.20

KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial

New 90-day high: €14.60

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

New 90-day high: €11.90

New 90-day high - €11.60

First quarter earnings released

New 90-day high - €11.50

New 90-day low - €8.55

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad